Along with distress that comes with cancer diagnosis and the discomfort of treatment, more patients now have to deal with “financial toxicity”, the expense, anxiety and loss of confidence confronting those who face large, unpredictable costs.
Researchers have now developed a tool to measure a patient’s risk for, and ability to tolerate, financial stress that comes with cancer.
Named COST (Comprehensive Score for financial Toxicity), the tool comprises 11 questions, assembled and refined from conversations with more than 150 patients with advanced cancer.
- Twitter War Between Congress Leader Amarinder Singh & Delhi CM Arvind Kejriwal
- Life Of Actor-Dancer Ashwini Ekbote Who Died During A Performance
- Idea Exchange With Gurmeet Ram Rahim Singh
- PM Narendra Modi Bats For Equal Rights : Here What He Said On Triple Talaq
- Uncle Shivpal Targets Akhilesh, Claims CM Told Him He Will Form Another Party
- Pakistan Continues To Violate Ceasefire In RS Pura
- Samajwadi Party’s internal fight divides SP
- Cyrus Mistry Removed As Chairman of Tata Sons: Here’s What Happened
- Wreath Laying Ceremony Of Slain Soldier Sushil Kumar Observed
- Virat Kohli Powers India Home With Unbeaten 154
- Pakistan Resorts To Heavy Mortar Shelling, 1 BSF Jawan Dead, 3 Injured
- Bigg Boss 10 Weekend Ka Vaar: Priyanka Jagga Evicted
- Here’s How Much Army Welfare Fund Has After MNS Demanded Rs 5 Cr To Cast Pak Artistes
- Shiv Sena Chief Uddhav Thackeray Take A Jibe At MNS: Here’s What He Said
- Samajwadi Party Crisis Deepens: Here’s How It Will Impact UP Polls
“A few physicians discuss this increasingly significant side effect with their patients,” said Jonas de Souza, head-and-neck cancer specialist at University of Chicago Department of Medicine in the US.
“We believe that a thoughtful, concise tool that could help predict a patient’s risk for financial toxicity might open the lines of communication. This gives us a way to launch that discussion,” de Souza added.
Explaining the utility of the tool, he noted, “If patients know what to expect, they may want their physicians to consider less costly medications.”
The findings appeared in the journal Cancer.